Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters

Fig. 4

Intracranial time to progression (iTTP) stratified by EGFR mutation subtypes. iTTP of patients with uncommon mutations and those with 19del (A) and those with L858R(B), before PSM; iTTP of patients with uncommon mutations and those with 19del (C) and those with L858R(D), after PSM

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us